Giovanni Mariggi, Ph.D.
Giovanni is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to Medicxi, Giovanni was a Principal at Index Ventures for four years, having joined in 2012. He led Medicxi’s investment in Obseva and currently serves on the boards of a number of portfolio companies, including Gadeta, SuperX, Kymo Therapeutics and Janpix.
Prior to joining Index, Giovanni was at Cancer Research UK's London Research Institute (now the Crick Institute) where he conducted research on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects in oncology as an independent consultant to various biopharma.
Giovanni received a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.